David A. Siegel Corvus Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 212,700 shares of CRVS stock, worth $1.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

212,700

Previous 236,400 10.03%

Holding current value

$1.53 Million

Previous $751,000 13.18%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$2.82 - $4.5 $66,834 - $106,650	-23,700 Reduced 10.03%	212,700 $850,000
Q1 2025 May 15, 2025	BUY	$3.18 - $6.03 $694,830 - $1.32 Million	218,500 Added 1220.67%	236,400 $751,000
Q4 2024 Feb 14, 2025	SELL	$4.55 - $9.56 $197,470 - $414,904	-43,400 Reduced 70.8%	17,900 $93,000
Q3 2024 Nov 14, 2024	SELL	$1.78 - $5.92 $92,738 - $308,432	-52,100 Reduced 45.94%	61,300 $323,000
Q2 2024 Aug 14, 2024	SELL	$1.36 - $2.29 $97,512 - $164,193	-71,700 Reduced 38.74%	113,400 $206,000
Q1 2024 May 15, 2024	SELL	$1.76 - $2.41 $88,880 - $121,705	-50,500 Reduced 21.43%	185,100 $329,000
Q4 2023 Feb 14, 2024	SELL	$1.08 - $1.92 $14,364 - $25,536	-13,300 Reduced 5.34%	235,600 $414,000
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.97 $98,841 - $208,197	70,100 Added 39.21%	248,900 $363,000
Q2 2023 Aug 14, 2023	SELL	$1.0 - $3.86 $8,500 - $32,810	-8,500 Reduced 4.54%	178,800 $409,000
Q1 2023 May 15, 2023	SELL	$0.65 - $0.92 $47,450 - $67,160	-73,000 Reduced 28.04%	187,300 $170,000
Q4 2022 Feb 14, 2023	SELL	$0.74 - $1.04 $162,652 - $228,592	-219,800 Reduced 45.78%	260,300 $221,000
Q3 2022 Nov 14, 2022	BUY	$0.71 - $1.17 $75,757 - $124,838	106,700 Added 28.58%	480,100 $393,000
Q2 2022 Aug 15, 2022	SELL	$0.87 - $2.03 $38,106 - $88,913	-43,800 Reduced 10.5%	373,400 $370,000
Q1 2022 May 16, 2022	SELL	$1.46 - $2.48 $505,452 - $858,576	-346,200 Reduced 45.35%	417,200 $684,000
Q4 2021 Feb 14, 2022	BUY	$2.34 - $5.31 $1.79 Million - $4.05 Million	763,400 New	763,400 $1.84 Million
Q3 2021 Nov 15, 2021	SELL	$1.89 - $8.53 $544,887 - $2.46 Million	-288,300 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.46 - $3.14 $9,102 - $11,618	-3,700 Reduced 1.27%	288,300 $770,000
Q1 2021 May 17, 2021	BUY	$2.86 - $4.77 $835,120 - $1.39 Million	292,000 New	292,000 $899,000
Q3 2020 Nov 16, 2020	SELL	$2.6 - $5.37 $95,888 - $198,045	-36,880 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.01 - $4.05 $16,079 - $32,400	8,000 Added 27.7%	36,880 $100,000
Q1 2020 May 15, 2020	BUY	$1.74 - $5.98 $21,402 - $73,554	12,300 Added 74.19%	28,880 $61,000
Q4 2019 Feb 14, 2020	BUY	$2.56 - $5.44 $42,444 - $90,195	16,580 New	16,580 $90,000

Others Institutions Holding CRVS

# of Institutions

102

Shares Held

38.8M

Call Options Held

98.5K

Put Options Held

226K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $335M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account